These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35641860)

  • 41. Long-Term Clinical Outcome in Systemic Lupus Erythematosus Patients Followed for More Than 20 Years: The Milan Systemic Lupus Erythematosus Consortium (SMiLE) Cohort.
    Gerosa M; Beretta L; Ramirez GA; Bozzolo E; Cornalba M; Bellocchi C; Argolini LM; Moroni L; Farina N; Segatto G; Dagna L; Caporali R
    J Clin Med; 2022 Jun; 11(13):. PubMed ID: 35806873
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunomodulatory effects of H.P. Acthar Gel on B cell development in the NZB/W F1 mouse model of systemic lupus erythematosus.
    Decker DA; Grant C; Oh L; Becker PM; Young D; Jordan S
    Lupus; 2014 Jul; 23(8):802-12. PubMed ID: 24759631
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus.
    Furie R; Morand EF; Askanase AD; Vital EM; Merrill JT; Kalyani RN; Abreu G; Pineda L; Tummala R
    Lupus; 2021 Jul; 30(8):1254-1263. PubMed ID: 33977796
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus.
    Ho A; Magder LS; Barr SG; Petri M
    Arthritis Rheum; 2001 Oct; 44(10):2342-9. PubMed ID: 11665975
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial.
    Fiechtner JJ; Montroy T
    Lupus; 2014 Aug; 23(9):905-12. PubMed ID: 24795067
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus.
    Iaccarino L; Bettio S; Reggia R; Zen M; Frassi M; Andreoli L; Gatto M; Piantoni S; Nalotto L; Franceschini F; Larosa M; Fredi M; Punzi L; Tincani A; Doria A
    Arthritis Care Res (Hoboken); 2017 Jan; 69(1):115-123. PubMed ID: 27390293
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Psychometric properties of FACIT-Fatigue in systemic lupus erythematosus: a pooled analysis of three phase 3 randomised, double-blind, parallel-group controlled studies (BLISS-SC, BLISS-52, BLISS-76).
    Rendas-Baum R; Baranwal N; Joshi AV; Park J; Kosinski M
    J Patient Rep Outcomes; 2021 Apr; 5(1):33. PubMed ID: 33830377
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.
    Clowse ME; Wallace DJ; Furie RA; Petri MA; Pike MC; Leszczyński P; Neuwelt CM; Hobbs K; Keiserman M; Duca L; Kalunian KC; Galateanu C; Bongardt S; Stach C; Beaudot C; Kilgallen B; Gordon C;
    Arthritis Rheumatol; 2017 Feb; 69(2):362-375. PubMed ID: 27598855
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current role of rituximab in systemic lupus erythematosus.
    Mok CC
    Int J Rheum Dis; 2015 Feb; 18(2):154-63. PubMed ID: 25522652
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Belimumab: review of use in systemic lupus erythematosus.
    Boyce EG; Fusco BE
    Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low-dose belimumab for patients with systemic lupus erythematosus at low disease activity: protocol for a multicentre, randomised, double-blind, placebo-controlled clinical trial.
    Sun F; Huang W; Chen J; Zhao L; Zhang D; Wang X; Wan W; Dai SM; Chen S; Li T; Ye S
    Lupus Sci Med; 2022 Feb; 9(1):. PubMed ID: 35105722
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA.
    Isenberg DA; Allen E; Farewell V; D'Cruz D; Alarcón GS; Aranow C; Bruce IN; Dooley MA; Fortin PR; Ginzler EM; Gladman DD; Hanly JG; Inanc M; Kalunian K; Khamashta M; Merrill JT; Nived O; Petri M; Ramsey-Goldman R; Sturfelt G; Urowitz M; Wallace DJ; Gordon C; Rahman A
    Ann Rheum Dis; 2011 Jan; 70(1):54-9. PubMed ID: 20833737
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Repository Corticotropin Injection (Acthar
    Wirta D; McLaurin E; Ousler G; Liu J; Kacmaz RO; Grieco J
    Ophthalmol Ther; 2021 Dec; 10(4):1077-1092. PubMed ID: 34669183
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Repository corticotropin injection versus corticosteroids for protection against renal damage in a focal segmental glomerulosclerosis rodent model.
    Hayes K; Warner E; Bollinger C; Wright D; Fitch RM
    BMC Nephrol; 2020 Jun; 21(1):226. PubMed ID: 32539845
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Follow-up results of myositis patients treated with H. P. Acthar gel.
    Saygin D; Oddis CV; Marder G; Moghadam-Kia S; Nandkumar P; Neiman N; Dzanko S; Koontz D; Aggarwal R
    Rheumatology (Oxford); 2020 Oct; 59(10):2976-2981. PubMed ID: 32160301
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Repository corticotropin injection in patients with refractory psoriatic arthritis: a case series.
    Brown AN
    Open Access Rheumatol; 2016; 8():97-102. PubMed ID: 27956846
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adrenocorticotropic hormone gel in the treatment of systemic lupus erythematosus: A retrospective study of patients.
    Li X; Golubovsky J; Hui-Yuen J; Shah U; Olech E; Lomeo R; Singh V; Busch H; Strandberg MJ; Strandberg K; Horowitz L; Askanase A
    F1000Res; 2015; 4():1103. PubMed ID: 27158444
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus.
    Ho A; Barr SG; Magder LS; Petri M
    Arthritis Rheum; 2001 Oct; 44(10):2350-7. PubMed ID: 11665976
    [TBL] [Abstract][Full Text] [Related]  

  • 59. American College of Rheumatology Provisional Criteria for Global Flares in Childhood-Onset Systemic Lupus Erythematosus.
    Brunner HI; Holland M; Beresford MW; Ardoin SP; Appenzeller S; Silva CA; Flores F; Goilav B; Wenderfer SE; Levy DM; Ravelli A; Khunchandani R; Avcin T; Klein-Gitelman MS; Feldman BM; Ruperto N; Ying J;
    Arthritis Care Res (Hoboken); 2018 Jun; 70(6):813-822. PubMed ID: 29693328
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of standard of care treatments and disease variables on outcomes in systemic lupus erythematosus trials: analysis from the Lupus Foundation of America Collective Data Analysis Initiative.
    Kalunian KC; Kim M; Xie X; Baskaran A; Daly RP; Merrill JT
    Eur J Rheumatol; 2016 Mar; 3(1):13-19. PubMed ID: 27708963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.